Radioimmunotherapy with 131I-rituximab: What we know and what we don't know

Cancer Biotherapy and Radiopharmaceuticals

Volumn 18, Issue 4, 2003, Pages 489-495

  Juweid, Malik E ^a,b  

^a UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

^b UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BILIRUBIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; IBRITUMOMAB TIUXETAN; LIVER ENZYME; PREDNISONE; RADIOPHARMACEUTICAL AGENT; RITUXIMAB; RITUXIMAB I 131; TOSITUMOMAB; UNCLASSIFIED DRUG; VINCRISTINE; IODINE 131 ANTI B1 ANTIBODY; IODINE-131 ANTI-B1 ANTIBODY; MONOCLONAL ANTIBODY; RADIOACTIVE IODINE;

ANTINEOPLASTIC ACTIVITY; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CLINICAL TRIAL; DOSIMETRY; DRUG EFFICACY; EDITORIAL; FEVER; HUMAN; NAUSEA; NEPHROTOXICITY; NONHODGKIN LYMPHOMA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RADIATION DOSE DISTRIBUTION; RADIOIMMUNOTHERAPY; RADIOIODINATION; SIDE EFFECT; TREATMENT OUTCOME; NOTE;

ANTIBODIES, MONOCLONAL; HUMANS; IODINE RADIOISOTOPES; RADIOIMMUNOTHERAPY;

EID: 0041335504     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/108497803322287565     Document Type: Editorial

References (31)

1. Reff ME, Carner K, Chambers KS, et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994;83:435.
2. Maloney DG, Grillo-López AJ, Bodkin DJ, et al. IDEC-C2B8: Results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma. J Clin Oncol 1997;15:3266.
3. McLaughlin P, Grillo-López AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody for relapsed indolent lymphoma: Half of patients respond to four-dose treatment program. J Clin Oncol 1998;16: 2825.
4. Piro LD, White CA, Grillo-López AJ, et al. Extended Rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low grade or follicular non-Hodgkin's lymphoma. Ann Oncol 1999;10:655.
5. Davis TA, Grillo-López AJ, White CA, et al. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: Safety and efficacy of re-treatment. J Clin Oncol 2000;18:3135.
6. Coiffier B, Haion C, Ketterer, et al. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma. A multicenter phase II study. Blood 1998;92: 1927.
7. Czuczman MS, Grillo-López AJ, White CA, et al. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol 1999;17:268.
8. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus Rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002;346:235.
9. Gregory SA, Venugopal P, Adler S, et al. Combined fludarabine, mitoxantrone, and rituximab achieves a high response as initial treatment for advanced low grade non-Hodgkin?s lymphoma. Blood 2002;100:362a (abstract).
10. Upendra H, White T, Stetler-Stevenson M, et al. Phase I study of combination rituximab (CD20) and apolizumab (Hu1D10) monoclonal antibody therapy in previously treated B-cell lymphoma and chronic lymphocytic leukemia. Blood 2002;100:358a (abstract).
11. 131I-Anti CD20 radioimmunotherapy of relapsed refractory non-Hodgkin's lymphoma: A phase II clinical trial of a nonmyeloablative dose regimen of chimeric rituximab radiolabeled in a hospital. Cancer Biother Radiopharm 2003;18:513.
12. Behr TM, Wormann B, Gramatzki M, et al. Low-versus high-dose radioimmunotherapy with humanized anti-CD22 or chimeric anti-CD20 antibodies in a broad spectrum of B cell-associated malignancies. Clin Cancer Res 1999;5:3304s.
13. Behr TM, Griesinger F, Riggert, et al. High-dose myeloablative radioimmunotherapy of mantle-cell non-Hodgkin's lymphoma with the iodine-131-labeled chimeric anti-CD20 antibody C2B8 and autologous stem cell support. Cancer 2002;94:1363.
14. Behr TM, Gotthardt M, Gratz S, et al. High-dose myeloablative versus conventional low-dose radioimmunotherapy (RIT) of mantle-cell lymphoma (MCL) with the chimeric anti-CD20 antibody C2B8. J Nucl Med 2002;43:115P (abstract).
15. Scheidhauer K, Wolf I, Rose C, et al. Can FDG-PET predict outcome after radioimmunotherapy in recurrent non-Hodgkin's lymphoma. J Nucl Med 2002;43:78P (abstract).
16. 131I-labeled anti-CD20 MAb IDEC-C2B8 (rituximab) in relapsed non-Hodgkin's lymphoma. Eur J Nucl Med 2002;29:1276.
17. Antonescu C, Buchegger F, Kosinski M, et al. Biokinetics of multiple dose I-131-labeled and unlabeled chimeric anti-CD20 antibody (rituximab) in patients with non-Hodgkin's lymphoma. Eur J Nucl Med Suppl 2002;29:S149.
18. Juweid ME. Radioimmunotherapy of B-cell non-Hodgkin's lymphoma: From clinical trials to clinical practice. J Nucl Med 2002;43:1507.
19. Kozak RW, Raubitschek A, Mirzadeh S, et al. Nature of the bifunctional chelating agent used for radioimmunotherapy with yttrium-90 monoclonal antibodies: Critical factors in determining in vivo survival and organ toxicity. Cancer Res 1989;49:2639.
20. Zevalin [package insert]. San Diego, CA IDEC Pharmaceuticals Corp; 2002.
21. 131I]anti-B1 (anti-CD20) antibody. N Engl J Med 1993;329:459.
22. Kaminsky MS, Zasadny KR, Francis IR, et al. Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma. J Clin Oncol 1996;14:1974.
23. Kaminski MS, Estes J, Zasady, et al. Radioimmunotherapy with iodine 1-131 tositumomab for relapsed or refractory B-cell non-Hodgkin's lymphomas: Updated results and long-term follow-up of the University of Michigan experience. Blood 2000;96:1259.
24. Gregory SA, Leonard J, Coleman M, et al. Bexxar™ (Tositumomab, Iodine 131 Tositumomab) can be safely administered in relapsed low-grade or transformed low-grade non-Hodgkin's lymphoma (NHL) patients after prior treatment with Rituximab: Initial experience from the expanded access study. Blood 1999;94(10 suppl 1):91a.
25. Press OW, Eary JF, Appelbaum FR, et al. Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support. N Engl J Med 1993; 329:1219.
26. 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B-cell lymphomas. Lancet 1995;346:336.
27. Witzig T, White C, Wiseman G, et al. Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20+ B-cell non-Hodgkin's lymphoma. J Clin Oncol 1999;17:3793.
28. Witzig TE, Gordon LI, Cabanillas F, et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus Rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol 2002;20:2453.
29. Wiseman G, White CA, Sparks, et al. Biodistribution and dosimetry results from the phase III prospectively randomized controlled trial of Zevalin radioimmunotherapy for low-grade, follicular, or transformed B-cell NHL. Crit Rev Oncol Hematol 2001; 39:181.
30. Knox SJ, Goris ML, Trisler K, et al. 90Yttrium labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma. Clin Cancer Res 1996;2:457.
31. 131I-anti-CD20 radioimmunotherapy for relapsed or refractory mantle cell lymphoma: Radiation absorbed dose evaluation. J Nucl Med 2001;42:157P (abstract).